Summary of the latest price of Sotolaxib (AMG 510) and factors affecting changes in drug prices

Sotoracib is a KRAS G12C small molecule inhibitor, mainly used to treat patients with KRAS G12C mutation-positive non-small cell lung cancer (NSCLC). At present, the drug is not yet on the market in China, so domestic patients cannot purchase it directly through formal channels and can only obtain it through overseas channels. In the overseas market, the original drug of sotorasibu mainly includes the European version and the Hong Kong version. The price is relatively expensive, generally around tens of thousands of yuan, which is a heavy financial burden for most patients.

In contrast, the prices of generic drugs in overseas markets are more affordable. For example, the price of generic drugs of sotorasibu produced in Laos has been significantly reduced recently. The generic drug of 120mg*56 tablets now only costs more than 1,000 yuan. This type of generic drug is basically the same as the original drug in terms of ingredients and can provide similar therapeutic effects. It provides a feasible economic option for patients in urgent need of the drug and significantly reduces the cost of medication.

Factors affecting changes in drug prices of sotorasibu mainly include research and development costs, market supply and demand, drug channels and policy regulation. The high price of original drugs is mainly due to the huge investment in research and development, high clinical trial costs and limited supply in the initial stage of marketing. After generic drugs are launched on the market, their prices are usually significantly lower than those of original drugs due to lower production costs, increased competition, and different marketing strategies.

In addition, policy factors and international market dynamics also affect drug prices. The price reduction of overseas generic drugs is often related to the optimization of production costs, intensified market competition, and adjustments to pricing strategies by pharmaceutical companies. For domestic patients, if sotorasibu is officially approved for marketing or included in medical insurance in China in the future, its price and reimbursement policies may be further adjusted, thereby improving the accessibility and affordability of the drug. During this period, when choosing overseas drugs, patients should give priority to purchasing them through formal channels and use them safely in conjunction with doctor's guidance.

Reference link:https://www.drugs.com